Latest action: Referred to the House Committee on Energy and Commerce.
Referred to one or more standing committees for review, hearings, and possible markup.
Specific committees not parsed from action data.
The committee may hold hearings, amend the bill, or let it die without action.
Next: Reported
Full chamber floor — Speaker / Majority Leader controls scheduling
Bill aims to speed up development of cancer treatments specifically for children.
The problem
Children with cancer need new treatment options faster. Current development processes take many years, and some childhood cancers lack effective treatments.
The proposal
The bill likely creates programs or funding to accelerate research, testing, and approval of cancer medicines designed for kids with various cancer types.
The impact
Pediatric cancer patients and their families may benefit from faster access to new treatments. Research institutions and pharmaceutical companies working on childhood cancer drugs would be affected.
Accelerating research could bring new cancer drugs to sick children sooner. This may save lives and improve survival rates for children battling cancer.
Directing resources specifically toward childhood cancer addresses a serious medical need. This focused approach could lead to breakthroughs in treating cancers that affect children.
Faster access to better treatments means children endure less pain and suffering. Families facing childhood cancer would have more hope and treatment choices.
Speeding up approval processes could potentially reduce testing time for safety. If not carefully managed, faster timelines might miss important side effects.
Accelerated research and development programs require significant funding. Taxpayers would bear the cost, and money diverted here cannot fund other programs.
New treatments developed through this program might initially be expensive. Only wealthy families or those with good insurance might access breakthrough treatments first.
Generated by AI from the bill text. Not a prediction and not legal or policy advice. The percentage is the model's own rating of each item — self-reported, and not a measure of how accurate it is.
Loading map…
Loading...
0 citizens have already voted
Free · No spam · See how your representatives voted
Be the first to weigh in
Your vote starts the conversation
How citizen engagement works
Citizens vote & comment
Public opinion data is aggregated and updated in real time.
Patterns become visible
Representatives can see constituent sentiment broken down by district.
Your voice on the record
Contact your rep directly — one constituent call can shift a staffer's priority list.
Research shows that constituent contacts — especially calls — are among the most effective ways to influence a legislator's position on active bills.
Individual contributions, grouped by employer · FEC
Where their individual donors work · 2026 cycle
Money from people who work there, not from the company. Not tied to this bill.
Itemized individual contributions via FEC, grouped by the employer each contributor self-reported. Companies and unions cannot contribute to federal candidates from their treasuries, so these totals are money from people who work at an employer — never from the organization itself. They are campaign contributions covering a full election cycle and are not connected to this bill.
Senate LDA lobbying disclosures
Couldn't load lobbying disclosures right now.